TABLE OF CONTENTS

1. Overview 7
   1.1 Objectives of the Report 7
   1.2 Methodology 8
   1.3 Scope of the Report 9
   1.4 Executive Summary 10

2. IVD Clinical Hematology Analyzer Market 11
   2.1 Introduction 11
   2.2 Key Product Segments 16
     2.2.1 Hematology and Associates Instruments 16
       2.2.1.1 Hematology Analyzers 16
       2.2.1.2 Hematology Instruments Offerings by Major Players 17
       2.2.1.2.1 Hematology Reagents and Controls 18
       2.2.1.2.2 Hematology Point of Care Instruments 19
       2.2.1.3 Flow Cytometers 20
         2.2.1.3.1 Flow Cytometry Technology Platforms 20
         2.2.1.3.2 Clinical Applications of Flow Cytometry 21
           2.2.1.3.2.1 Leukocyte Analysis 21
           2.2.1.3.2.2 Immunophenotyping of Leukemias and Lymphomas 21
           2.2.1.3.2.3 Neutropenia 21
           2.2.1.3.2.4 Platelet Analysis 21
           2.2.1.3.2.5 T Cell Subsets 22
           2.2.1.3.2.6 Reticulocyte Count 22
         2.2.1.3.3 Flow Cytometry Market Growth 22
           2.2.1.3.3.1 Applications 23
           2.2.1.3.3.2 Market Size 23
           2.2.1.3.3.3 Instrumentation Preferences 24
           2.2.1.3.3.4 Reagent Selection and Use 25
           2.2.1.3.3.5 Instrument Manufacturers 25
           2.2.1.3.3.6 Future Directions of Flow Cytometry 26
       2.2.1.4 Coagulation Analyzers 27
         2.2.1.4.1 Coagulation Market Size 27
         2.2.1.4.2 Prothrombin Time Test 28
         2.2.1.4.3 Activated Partial Thromboplastin Time (APTT) 29
         2.2.1.4.4 Clinical Advantages of Coagulation Testing 29
       2.2.1.5 Hemoglobinometers 33
       2.2.1.6 Slide Stainers 34
     2.2.2 Hematology Tests 37
       2.2.2.1 Complete Blood Count (CBC) 37
       2.2.2.2 Red Blood Cells (RBCs) 38
       2.2.2.3 White Blood Cells (WBCs) 38
       2.2.2.4 Platelets 38
       2.2.2.5 Hematocrit (HCT) 39
       2.2.2.6 The Coulter Principle 40
2.6 Blood Collection

3. Global Analyzer Market
   3.1 Global Markets
      3.1.1 Global Drivers of Clinical Hematology Analyzer Testing
      3.1.2 Global Outlook
      3.1.3 U.S. Market
      3.1.4 European Market
      3.1.5.1 German Clinical Hematology Analyzer and Reagent Diagnostic Markets
      3.1.5.2 U.K. Clinical Hematology Market
      3.1.5.3 French Clinical Hematology Market
      3.1.5.4 Italian Clinical Hematology Market
      3.1.5.5 Spanish Clinical Hematology Market
      3.1.5.6 Belgian Clinical Hematology Market
      3.1.5.7 Swiss Clinical Hematology Market
      3.1.5.8 Dutch Clinical Hematology Market
      3.1.5.9 Portuguese Clinical Hematology Market
      3.1.5.10 Austrian Clinical Hematology Market
      3.1.5.11 Greek Clinical Hematology Market
      3.1.5.12 Polish Clinical Hematology Market
      3.1.5.13 Czech Clinical Hematology Market
      3.1.5.14 Finnish Clinical Hematology Market
      3.1.5.15 Scandinavian Clinical Hematology Market
      3.1.6 Asian Market
         3.1.6.1 Indian Clinical Hematology Market
         3.1.6.1.1 India’s in vitro Diagnostic Testing Industry
         3.1.6.1.2 Major Indian IVD Companies
         3.1.6.2 Japanese Clinical Hematology Market
         3.1.6.3 Chinese Clinical Hematology Market
      3.1.7 Country Clinical Hematology Smaller Markets
         3.1.7.1 Canada Clinical Hematology Market
         3.1.7.2 Brazil Clinical Hematology Market
         3.1.7.3 Turkey Clinical Hematology Market
         3.1.7.4 Australia Clinical Hematology Market
         3.1.8 Remaining World Clinical Hematology Market
      3.1.9 Overview of Asian Healthcare Market
         3.1.9.1 Singapore
         3.1.9.2 Malaysia
         3.1.9.3 Thailand
         3.1.9.4 Indonesia
         3.1.9.5 Philippines
         3.1.9.6 South Korea
         3.1.9.7 Hong Kong
      3.1.10 Overview of the Latin American Diagnostics Market
   3.2 Clinical Hematology Analyzer and Reagents Sector
      3.2.1 Industry-Served Markets
      3.2.2 Industry Players
         3.2.2.1 Manufacturing Companies
         3.2.3 Market Specialization
      3.2.4 Hematology Sector Companies
      3.3 Outlook for Clinical Hematology Analyzer Testing
         3.3.1 Long-Term Changes
         3.3.2 Market Drivers
         3.3.3 The Limits to Growth
         3.3.4 Hot Sectors in the IVD Market
         3.3.5 Key Technologies
3.3.6 Conclusion 76

4. Clinical Hematology Instrument Market by Type and Competitor 77
   4.1 Abbott Diagnostics 77
   4.2 Siemens Healthcare Diagnostics 80
   4.3 Beckman Coulter, Inc. 81
   4.4 Drew Scientific Group 83
   4.5 Horiba ABX Inc. 84
   4.6 Sysmex Corporation 85
   4.7 Boule Medical AB 90
   4.8 Beijing ShiningSun Technology Co., Ltd. 91
   4.9 Hematology Analyzers for Point of Care 91

5. Important Technology Trends 92
   5.1 Technology Platform Innovations in Hematology Testing 92
   5.2 The New Paradigm 92
   5.3 Consolidated Workstations 92
   5.4 Automation in the Laboratory 94
   5.5 Laboratory Information Systems 95
   5.6 New User-friendly Interfaces 96
   5.7 Data-Management Issues 97
   5.7.1 Wireless LANs 97
   5.7.2 Data and Workflow Management Systems 98
   5.7.3 Beckman Central Command Central Version 2.0 98
   5.7.4 Middleware 98
   5.8 Robotics - Total Laboratory Automation Robotic Sample Handling 99
   5.9 Image Analysis 100
   5.10 Flow Cytometry 100
   5.11 Laser Technology 101
   5.12 Automating Preanalytics 101
   5.13 Telepathology 101

6. Business Trends in the Clinical Hematology Analyzer Sector 103
   6.1 Key Developments 103
   6.2 Industrial Sector Consolidation 103
   6.3 Hospital and Commercial Laboratory Consolidation 105
   6.4 Changing Ordering Patterns 106
   6.5 New Products 106
   6.6 Acquisition, License Agreements, Internal Development and Partnerships 108
   6.7 Breadth of Product Offerings 108
   6.8 Government Regulation 111
   6.8.1 U.S. Regulation 111
   6.8.1.1 Importing Medical Devices into the U.S. 112
   6.8.1.2 Exporting Medical Devices from the U.S. 113
   6.8.2 U.K. Regulation 113
   6.8.3 E.U. Regulation 114
   6.8.4 Japanese Regulation 117
   6.8.5 Korean Regulation 117
   6.9 Costs of Doing Business in Europe 118
   6.10 Drivers of European Diagnostics Testing 118
   6.11 European Reimbursement Practices 118
   6.12 Cost Containment in Europe 118
   6.13 Revenue and Reimbursement 118

7. Product Launches 120
   7.1 Horiba ABX Unveils Pentra DX 120 120
7.2 Sysmex to Launch Sales of the XT-4000i Hematology Analyzers 120
7.3 Laser Scan Cytometry System 121
7.4 Abbott Receives Clearance for Hematology Instrument 121
7.5 Vital Diagnostics announced the Addition of the Excyte Mini Automated ESR Analyzer 121
7.6 Becton Introduces FACSCanto II 121
7.7 Abbott’s International Launch of CELL-DYN Emerald™ Hematology Instrument 122
7.8 Beckman Coulter Launches UniCel DxH 800 122
7.9 Beckman Launches High-Performance Hematology Analyzer Ac•T 123
7.10 Abbott Laboratories Released its Cell-Dyn 1800 Automated Hematology Analyzer 123
7.11 BD (Becton Dickinson Biosciences) Imagn System 123
7.12 Sysmex Network Communications System 123
7.13 Sysmex XT-V Multi-Species Hematology Analyzer 123
7.14 The Melet Schloesing MS4-5 124
7.15 Roche CoaguChek XS Plus System 124
7.16 Sysmex Corp Launches KX-4500 124
7.17 Streck nRBC-Chex 124
7.18 HORIBA ABX Introduces Micros CRP 200 124
7.19 Hesa Corporation Introduces Veterinary Hematology Analyzer 124
7.20 Specialized Master Software Programs for the Sysmex XE-2100 Hematology Analyzers 125
7.21 HORIBA ABX e-Sat module 125
7.22 Medonic M series Hematology Analyzer 125
7.23 Streck’s ESR-AutoPlus 125
7.24 Streck Quality Control Reagents 125

8. Clinical Hematology Testing Sector Trends and Forecasts 126
8.1 Home Care Analysis 126
8.2 Non-Traditional Collection for Hematology Analyzer Testing 126
8.3 New Systems for Critical-Care and Near-Patient Testing 126
8.4 Utility of Near-Patient Testing in Critical-Care Settings 126
8.5 Mergers of Diagnostic Companies 126
8.6 Information Management Advances 126
8.7 Test Ordering Patterns 126
8.8 Patient Satisfaction 126
8.9 Move Away From Central Laboratory 127
8.10 Healthcare Cost Controls 127
8.11 Competition for Services 127
8.12 Drivers of Clinical Hematology analyzer Testing 127
8.13 Confluence of New Technology 127
8.14 New Trends in Clinical Laboratory Testing 128
8.14.1 Trends in Reimbursement Practices 128
8.14.2 Managed Care 130
8.14.3 Changes in Patient Management 131
8.14.4 Focused Testing 131
8.14.5 Satellite Facilities 131
8.15 Demographic Trends 131

9. Company Profiles 132
9.1 Abbott Diagnostics 132
9.2 A.Menarini Diagnostics 133
9.3 Bayer HealthCare, AG 134
9.4 Beckman Coulter, Inc. 135
9.5 Becton Dickenson Biosciences 139
9.6 Boule Diagnostics International AB 140
9.7 Cholestech Corporation 140
9.8 Dade Behring (Acquired by Siemens) 141
9.9 HemoCue, Inc. 141
9.10  Heska Corporation  141
9.11  Horiba Group  142
9.12  MELET SCHLOESING Laboratories  142
9.13  Micronics, Inc.  143
9.14  Nihon Kohden Corporation  143
9.15  PPD (Pharmaceutical Product Development, Inc.)  144
9.16  Roche Diagnostics (F. Hoffmann-La Roche, Ltd.)  144
9.17  Shenzhen Mindray Bio-Medical Electronics Co. Ltd.  145
9.18  Streck, Inc.  145
9.19  Sysmex Corporation  146

LIST OF TABLES

Table 2.1:  Clinical Hematology Tests Submitted to Medicare, 2005-2012  12
Table 2.2:  Clinical Hematology Tests Performed in the U.S., 2005-2012  12
Table 2.3:  Allowed Charges for Top 25 Clinical Laboratory Procedures, 2009  13
Table 2.4:  Competitive Landscape: Companies Participating in the Hematology IVD Sector  14
Table 2.5:  Key Product Segments  16
Table 2.6:  Worldwide Market for Flow Cytometry Instruments and Reagents, 2000-2010  24
Table 2.7:  Worldwide Market for Rapid Coagulation Testing Dollar Volume, 2000-2008  28
Table 2.8:  U.S. Market for Rapid Coagulation Testing Dollar Volume, 2000-2008  28
Table 2.9:  U.S. Market for Rapid Coagulation POC Testing Dollar Volume, 2001-2012  28
Table 2.10:  Slide Stainer Instruments and Manufacturers  35
Table 2.11:  Hematology Stains  37
Table 2.12:  The Overall In Vitro Diagnostic Testing Market Worldwide, 2008  41
Table 2.13:  Worldwide Distribution of IVD Testing, 2008  41
Table 2.14:  Global Clinical Hematology Analyzer and Reagent Revenues, 2005-2012  42
Table 2.15:  Worldwide Distribution of Clinical Hematology Testing Analyzer and Reagent Revenues, 2006  42
Table 2.16:  Ten Largest Diagnostic Companies Worldwide, 2007  43
Table 2.17:  Key Players in Worldwide Hematology Analyzers and Reagent Market  43
Table 2.18:  Leading Players in Worldwide Coagulation Analyzer and Reagent Market  44
Table 2.19:  U.S. Clinical Hematology Analyzer Testing Market, 2000-2011  46
Table 2.20:  U.S. Clinical Laboratory Diagnostic Test Market Segments, 2007  46
Table 2.21:  Leading Players in the U.S. Hematology Analyzers Market  47
Table 2.22:  Leading Players in the U.S. Coagulation Analyzers Market  47
Table 2.23:  European Clinical Laboratory Testing IVD Reagents and Instruments Market, 2000-2012  49
Table 2.24:  European Clinical Laboratory Testing Diagnostics by Country Market Estimates, 2007  49
Table 2.25:  European Clinical Hematology Instrument and Reagent Testing Market, 2000-2008  50
Table 2.26:  German Hematology Reagent Market Sales, 2003-2012  51
Table 2.27:  UK Hematology Reagent Market Sales, 2003-2012  53
Table 2.28:  French Hematology Reagent Market Sales, 2003-2012  53
Table 2.29:  Italian Hematology Reagent Market Sales, 2003-2012  54
Table 2.30:  Spanish Hematology Reagent Market Sales, 2003-2012  54
Table 2.31:  Belgian Hematology Reagent Market Sales, 2003-2012  55
Table 2.32:  Swiss Hematology Reagent Market Sales, 2003-2012  55
Table 2.33:  Dutch Hematology Reagent Market Sales, 2003-2012  55
Table 2.34:  Portuguese Hematology Reagent Market Sales, 2003-2012  56
Table 2.35:  Austrian Hematology Reagent Market Sales, 2003-2012  56
Table 2.36:  Greek Hematology Reagent Market Sales, 2003-2012  57
Table 2.37:  Polish Hematology Reagent Market Sales, 2003-2012  57
Table 2.38:  Czech Hematology Reagent Market Sales, 2003-2012  57
Table 2.39:  Finnish Hematology Reagent Market Sales, 2003-2012  58
Table 2.40:  Scandinavian Clinical Hematology Diagnostics Products Market Sales, 2002-2008  58
Table 2.41:  Indian IVD Market, 2006-2012  59
Table 2.42:  Indian Hematology Reagent Market Sales, 2006-2012  59
Table 3.33: Number of Automated Clinical Labs in India, 2004-2012
Table 3.34: Indian IVD Market, 2008
Table 3.36: Japanese Clinical Hematology Testing Market, 2000-2008
Table 3.37: Chinese Clinical Hematology Reagent Market Sales, 2000-2008
Table 3.38: Canadian Clinical Hematology Testing Market, 2000-2008
Table 3.39: Brazilian Clinical Hematology Analyzer Testing Market, 2000-2008
Table 3.40: Turkish Clinical Hematology Reagents Testing Market, 2000-2008
Table 3.41: Australian Clinical Hematology Reagents Testing Market, 2000-2008
Table 3.42: The ROW Clinical Hematology Reagents Testing Market, 2000-2008
Table 3.43: Estimated Number of Clinical Laboratories in Latin America
Table 3.44: Principal Marketers of Automated Clinical Hematology Analyzer Instruments
Table 4.1: Linearity and Precision of Abbott CELL-DYN Hematology Analyzers
Table 4.2: Accuracy of the Automated Differential of Abbott CELL-DYN Analyzers
Table 4.3: Linearity and Precision of Siemens Hematology Analyzers
Table 4.4: Accuracy of the Automated Differential of Siemens Hematology Analyzers
Table 4.5: Linearity and Precision of Beckman Coulter Hematology Instruments
Table 4.6: Accuracy of the Automated Differential of Beckman Coulter Hematology Analyzers
Table 4.7: Linearity and Precision of Horiba ABX Hematology Analyzers
Table 4.8: Accuracy of the Horiba ABX Hematology Analyzers
Table 4.9: Linearity and Precision of Sysmex Hematology Analyzers
Table 4.10: Accuracy of the Sysmex Hematology Analyzers
Table 4.11: Comparison of Linearity and Precision of Top-of-the-Line Hematology Analyzers
Table 4.12: Comparison of Accuracy of the Top-of-the-Line Hematology Analyzers
Table 4.13: Hematology Analyzers with a 5-Part WBC Differential
Table 4.14: Hematology Analyzers with a Three-Part WBC Differential
Table 5.1: Applications for Wireless LAN Technology
Table 8.1: Medicare Billing Guidelines for Multi-channel Hematology Analyzer Tests
1. Overview

Clinical hematology analyzer analysis is one of the oldest and most important sectors of clinical laboratory analysis. The hematology instrument and reagent market is centered on a group of instruments called hematology analyzers. The term clinical hematology analyzer usually refers to an automated instrument for determining the presence, number and type of cellular elements in easily collected body fluids, such as blood. However, it is not necessarily limited to these determinations. The hematology analysis always includes determination of non-cellular parameters in blood, such as hemoglobin and hematocrit. Other closely related areas of clinical interest are coagulation and flow cytometry.

In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are rapidly fading both operationally and instrumentally. But for the sake of defining the subject to a reasonable size, the more traditional scope of clinical hematology analyzer will be the focus of this examination.

1.1 Objectives of the Report

The purpose of this report is to describe the specific segments of the global clinical hematology analyzer instrumentation and reagent marketplace. The review covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small-lab, as well as highly-automated large-lab, platforms and accessory equipment, such as reagents, supplies and add-on equipment from original equipment manufacturers.

The emphasis in this analysis is on those companies and products that are actively developing and marketing hematology analyzer products for the clinical setting, including hospitals, independent labs, physician’s offices and miscellaneous clinics. This study examines the clinical hematology analyzer instrumentation and reagent industry market segment in the U.S. and around the world. The regional markets and their differences are examined, including Europe, Japan and the rest of the world. Particular attention is paid to those areas of the clinical hematology analyzer instrumentation sector that are showing the greatest growth or the most innovation. This review attempts to answer the following questions:

- Which companies are the key players?
- What are the opportunities in clinical hematology analyzer instrumentation?
- What are the development trends in hematology?
- Where are the new market growth areas in hematology instruments?
- What are the most favored technology platforms for hematology instruments?
- Where is the hematology analyzer instrument technology taking us?
- How is immunological technology blending with hematology analyzer?

This examination reviews the market for clinical hematology analyzer instrumentation used in clinical practice. It defines the dollar volume of sales in each major regional and country market, and it analyzes the factors that influence the size and the growth of the individual market segments. The report details market sizes and growth rates for the U.S. and world markets.

The study surveys some of the primary companies known to be marketing, manufacturing or developing products for the clinical hematology analyzer instrumentation market for those sectors covered here. Each company is discussed in depth with a section on the history of the company, the product line, business and marketing analysis, and a subjective commentary of the position of the company in its market.
The benefits of this report are:

- In-depth analysis of the major sectors of the clinical hematology analyzer instrumentation and reagent marketplace, their sizes, growth rates and major drivers.
- Presentation of some of the emerging technology platforms, elucidating the potential areas that could gain traction in this market.
- Analysis of the partnerships and alliances the various key sector players have forged, as well as describing financings of these market participants, giving insight into potential market collaborations.
- Examination of new technology platforms in the U.S., Japan and Europe that seek to dominate this mature market, and to identify lead positions and potential future growth areas.

1.2 Methodology

The author of this report is a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in scientific writing and as a medical industry analyst. He has been a senior director of several large regional and national healthcare laboratories. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Health and Human Services (HHS) and U.S. federal agencies such as the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates’ databases and from TriMark’s private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark’s research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

Market Forecasts and Modeling

The numerical data on market size, growth rates and sales forecasts are obtained from a well-examined model based upon quantitative market information obtained from the leading global companies in the sector, private seminar presentations by company experts and public SEC filings. Many industry experts are also consulted to confirm these market estimates. The numbers used are washed of discounts and returns, and represent the final sale numbers. In addition, global numbers are assessed by region components as well, taking into account differences in market conditions between the U.S., Europe and Asian markets in particular.
**TriMark Publications Report, Research and Data Acquisition Structure**

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.

- Formulating a study outline with the assigned writer, including important items, as follows:
  - Market and product segment grouping, and evaluating their relative significance.
  - Key competitors’ evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
  - Supply chain research and analysis to identify any factors affecting the market.
  - New technology platforms and cutting-edge applications.

- Identifying the key technology and market trends that drive or affect these markets.

- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.

- Completing a confirmatory primary research assessment of the report’s findings with the assistance of expert panel partners from the industry being analyzed.

**1.3 Scope of the Report**

This report deals with the analysis of common constituents of blood in well and ill patients for specifically hematology related parameters. The two most important areas where such tests are measured are in the hospital and the independent clinical laboratories. The third place these tests are measured is in physician’s office laboratories (POLs). Newer areas of testing interest for these analytes can be satellite labs and pharmacies and corporate clinics. This study touches on coagulation analysis primarily because it is historically included in hematology laboratory procedures. But no effort is made to give a comprehensive analysis of the coagulation testing market. Flow cytometry is briefly examined because of its increasing use in clinical hematology diagnosis. Again, no effort is made to examine this area extensively.

This examination does not include the areas of blood collection and processing for transfusion. Segments like apheresis, blood grouping, tests for groups A, B, AB, O; and Rh factor, blood screening, antibody screening, infectious disease testing, development of new techniques to ensure safer blood supply, blood conservation, and cord blood banking are reserved for other market reports. Most of the time in clinical practice, these areas are specifically separated from hematology and designated blood banking. The emphasis in this report is on those companies and products that are actively developing and marketing clinical laboratory instrumentation and reagents and supplies for performing clinical hematology analyzer tests in clinical diagnostics. The reader should consult other TriMark Publications reports at http://www.trimarkpublications.com for a detailed discussion of the important individual market segments that are related to the in vitro diagnostics (IVD) market, such as molecular diagnostic testing, high-growth diagnostic test markets, blood gas and electrolytes, over-the-counter diagnostic testing markets, clinical chemistry, immunochemistry, and point of care testing (POCT).

The analysis touches on the specialty testing areas in clinical hematology analyzer diagnostic testing, such as coagulation, CBC profiling and special markers, since these segments are frequently a part of the overall analytical focus of companies marketing general laboratory automation equipment. However, no effort is made to quantify the size of the broader market involving blood typing, blood banking and blood product collections. The report does not cover what is generally characterized as immunochemistry analyzer instruments and reagents, nor chemistry or coagulation markets, or other diagnostic device markets, although many of the instruments, reagents and techniques in the clinical hematology analyzer diagnostics market segment are intimately associated with these broader areas.
Moreover, this examination does not cover disposable plastic supplies for the clinical laboratory or blood gases and electrolytes. All of these subjects are treated thoroughly in other TriMark Publications reports.

1.4 Executive Summary

Clinical hematology analyzer testing includes processes used to detect levels of enzyme, sugars, proteins and other substances in the blood in order to determine such clinical conditions as nutritional state, liver function, kidney function and others. Such testing is widely applied in identifying conditions like diabetes, hyperlipidemia and arteriosclerosis during clinical diagnoses and as a part of regular health checkups. Clinical hematology analyzer tests carried out within hospitals in the U.S. increased to $\text{xxxxxx}$ in $\text{yyyyyy}$. Most of these tests were performed as screening, or multi-channel tests, performed on automated hematology analyzer analyzers specifically designed for that purpose. Automated multi-channel testing addresses those tests that can be and are frequently done as groups and combinations on automated clinical hematology analyzer equipment. The global IVD market for all test types reached $\text{xxxxxx}$ in sales in $\text{yyyyyy}$, with the U.S., Europe and Japan comprising approximately $\text{xxxxxx}$, $\text{xxxxxx}$ and $\text{xxxxxx}$%, respectively. Five countries account for approximately $\text{xxxxxx}$% of the IVD market worldwide. $\text{xxxxxx}$ country markets account for $\text{xxxxxx}$% of total IVD sales. The size and growth of the global clinical hematology analyzer market has increased $\text{xxxxxx}$% per year with worldwide revenues for clinical hematology analyzer testing estimated to be $\text{xxxxxx}$.

$\text{xxxxxx}$ companies control approximately $\text{xxxxxx}$% of the total $\text{xxxxxx}$ diagnostics industry. The worldwide IVD market is estimated to be growing at $\text{xxxxxx}$% to $\text{xxxxxx}$% per year. Although more than $\text{xxxxxx}$ major companies are involved in the $\text{xxxxxx}$ global market for clinical diagnostics, only $\text{xxxxxx}$ have sales of over $\text{xxxxxx}$, creating an environment that is still ripe for consolidation and partnering. Of the top seven companies, only Beckman Coulter is not part of a larger corporate structure that includes a pharmaceutical division. TriMark believes that the global IVD market will continue to grow due to a number of key favorable industry trends:

- Demographic shifts resulting from the aging of the population and socio-economic improvements are expected to increase the overall level of demand for diagnostic testing.
- Increased focus on lowering total healthcare expenditures will likely increase demand for diagnostic testing as an effective tool to improve patient outcomes and reduce the costs of misdiagnosis through earlier and more accurate diagnosis and patient monitoring.
- Emerging markets will provide additional demand as economic improvements in these countries lead to increases in healthcare expenditures.
- Technological improvements in new tests, pathogens and markers will result in the increased use of diagnostics to aid in the diagnosis of diseases.
- Improvements in lower-cost POC/near-patient testing capabilities are expected to expand the application of diagnostic testing capabilities into non-laboratory settings (e.g., operating room, emergency room, acute care centers).
- Increased automation of diagnostic instruments is expected to lower the overall cost of diagnostic testing and thereby increase accessibility and demand.

In the U.S., approximately $\text{xxxxxx}$% of clinical diagnostic testing is currently conducted in hospital-based and commercial laboratories. Clinical hematology analyzer testing now represents $\text{xxxxxx}$% of the $\text{xxxxxx}$ U.S. market for clinical diagnostic testing reagents, controls and equipment and is projected to grow at an annual rate of $\text{xxxxxx}$% in the U.S. through $\text{yyyyyy}$, to a total of $\text{xxxxxx}$. Surveys show that $\text{xxxxxx}$% of hospitals with more than $\text{xxxxxx}$ beds have adopted some form of clinical hematology analyzer testing, with over $\text{xxxxxx}$% of the $\text{xxxxxx}$ U.S. hospitals (\text{xxxxxx}-bed size and larger) having installed some form of clinical hematology analyzer instrumentation. The specific category of IVD devices, which encompasses the sales of automated clinical hematology analyzers, had sales of approximately $\text{xxxxxx}$ in the U.S. in $\text{yyyyyy}$, and has increased to $\text{xxxxxx}$ in $\text{yyyyyy}$. This portion of the market had sales in North America, Western Europe and Japan that increased to $\text{xxxxxx}$. The worldwide clinical hematology analyzer instrument, reagent and supply segment of the IVD market increased to $\text{xxxxxx}$ in $\text{yyyyyy}$. This includes general hematology analyzers, electrolytes, enzymes, blood gases, lipids and urinalysis. In the U.S. this total market is $\text{xxxxxx}$.
2. IVD Clinical Hematology Analyzer Market

2.1 Introduction

Clinical hematology analyzer testing includes processes used to detect red and white blood cells, platelets, and other substances in the whole blood in order to determine general clinical conditions. Such testing is widely applied in identifying conditions like anemia, cancer and various blood disorders during clinical diagnoses and as a part of regular health checkups.

The most common hematology tests are performed by automated instruments as traditional routine clinical hematology analyzer tests that measure red and white cells and platelets, generally referred to as a complete blood count (CBC). Other hematology related IVD tests measure bodily functions, such as blood-clotting ability and oxygen-carrying functions, or measure the presence of infections or parasites.

The wide range and important nature of these tests have established CBC testing as an integral part of the managed-care environment, providing for accurate and timely patient diagnosis and treatment. Increasingly, CBC testing is being recognized as making a significant contribution to improving patient care and lowering total patient costs. CBC tests are performed in a number of different clinical settings, including:

- Hospitals.
- Reference laboratories.
- Physician’s offices.
- Ambulatory care centers.
- Nursing homes.

CBC is used in virtually every part of the health delivery system and test providers generally fall into a number of categories:

- Reference laboratories that conduct batteries of tests for physicians and hospitals.
- Hospital central clinical laboratories.
- Operating rooms.
- Emergency rooms.
- Stat laboratories.
- Near-patient and patient bedside testing.
- Physician’s offices.
- Walk-in clinics.
- Surgeries.
- Pharmacies and supermarkets that offer in-store testing.
- Individuals who purchase kits for self-testing (occult blood testing).

The number of clinical hematology analyzer tests carried out within hospitals, independent labs and POLs in the U.S. is estimated to grow to [number] tests per annum by [year], double the number performed in [year].